158958-53-3

Usage

Uses

Used in Pharmaceutical Industry:
(1-PyriMidin-2-ylpiperid-4-yl)MethylaMine, 97% is used as an intermediate for the synthesis of various drugs and organic compounds. Its unique structure and high purity make it a valuable component in the development of new pharmaceuticals.
Used in Agrochemical Production:
(1-PyriMidin-2-ylpiperid-4-yl)MethylaMine, 97% is used as a building block in the production of agrochemicals. Its versatility and stability contribute to the creation of effective and reliable agrochemical products.
Used in Specialty Chemicals:
(1-PyriMidin-2-ylpiperid-4-yl)MethylaMine, 97% is also utilized in the production of specialty chemicals. Its high purity and reactivity make it a suitable candidate for various applications in this industry.

Upstream product

• 7144-05-0 4-Aminomethylpiperidine 
• 1722-12-9 2-chloropyrimidine 

Relevant academic research and scientific papers

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters

With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial

N-substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as 92 antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents

A series of N-substituted 1-(2,3-dihydro-1,4-benzodioxin-2- yl)methylamine derivatives with D2 antagonist/5-HT(1A) partial agonist activity has been prepared as potential atypical antipsychotic agents. Optimization of in vitro receptor binding activity and in vivo activity in rodent models of psychosis has led to compound 24, which showed good affinities for human D2, D3, and 5-HT(1A) receptors but significantly less affinity for human α1 adrenoceptors and rat H1 and muscarinic receptors. In rodents, 24 showed functional D2-like antagonism and 5-HT(1A) partial agonism. After oral dosing, 24 showed good activity in rodent antipsychotic tests and very little potential to cause extrapyramidal side effects (EPS), as measured by its ability to induce catalepsy in rats only at very high doses. In the light of this promising profile of activity, 24 has been selected for clinical investigation as a novel antipsychotic agent with a predicted low propensity to cause EPS.